Suzanne George

Harvard University

Full Professor(heuristic)

Gastrointestinal Tumor Research and Treatment · Gastroenterology

h-index74

i10-index204

Publications634

Citations21,232

Grants

36 total · 4 active

NIH #5U2CCA252974-06

Count Me In: Partnering with patients to define the clinical and genomic landscape of rare aggressive sarcomas in children and adults

Expiring Soon

Amount: $3.4M
Period: 2020-09-01 → 2026-08-31
PIs: 4
Est. capacity / PI: ~0 students

Awarded at BROAD INSTITUTE, INC.

NIH #5U2CCA252974-05

Count Me In: Partnering with patients to define the clinical and genomic landscape of rare aggressive sarcomas in children and adults

Expiring Soon

Amount: $3.0M
Period: 2020-09-01 → 2026-08-31
PIs: 4
Est. capacity / PI: ~0 students

Awarded at BROAD INSTITUTE, INC.

NIH #5U2CCA252974-04

Count Me In: Partnering with patients to define the clinical and genomic landscape of rare aggressive sarcomas in children and adults

Expiring Soon

Amount: $1.8M
Period: 2020-09-01 → 2026-08-31
PIs: 4
Est. capacity / PI: ~0 students

Awarded at BROAD INSTITUTE, INC.

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

Influence score not yet computed for this professor.

Admission Signals

New paper: Clinicopathologic Study of 39 Mismatch Repair-deficient Sarcomas Demonstrates Recurrent Histologic Patterns and Supports Universal Screening of Pleomorphic Rhabdomyosarcoma, Uterine Leiomyosarcoma, and Undifferentiated and Unclassified Sarcomas (The American Journal of Surgical Pathology)2026-06-12
New NIH award: $3,419K — Count Me In: Partnering with patients to define the clinical and genomic landscape of rare aggressive sarcomas in children and adults2020-09-01
New NIH award: $2,951K — Count Me In: Partnering with patients to define the clinical and genomic landscape of rare aggressive sarcomas in children and adults2020-09-01
New NIH award: $1,849K — Count Me In: Partnering with patients to define the clinical and genomic landscape of rare aggressive sarcomas in children and adults2020-09-01
New NIH award: $2,028K — Count Me In: Partnering with patients to define the clinical and genomic landscape of rare aggressive sarcomas in children and adults2020-09-01

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0002-1284-8493

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 65

Clinicopathologic Study of 39 Mismatch Repair-deficient Sarcomas Demonstrates Recurrent Histologic Patterns and Supports Universal Screening of Pleomorphic Rhabdomyosarcoma, Uterine Leiomyosarcoma, and Undifferentiated and Unclassified Sarcomas
The American Journal of Surgical Pathology · 2026-06-12
Data from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
2026-06-01
Supplementary Tables 1-3 from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
2026-06-01
Phase 1a/1b study of the safety, pharmacokinetics, and antitumor activity of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure.
Journal of Clinical Oncology · 2026-05-28
First-in-human clinical evaluation of ST-01156, an optimized and selective degrader of RNA-binding motif 39 (RBM39): A phase 1 study in advanced solid malignancies with a focus on RBM39-dependent cancers.
Journal of Clinical Oncology · 2026-05-28
StrateGIST 3: A randomized, phase 3 study of velzatinib (IDRX-42) versus sunitinib in patients with advanced gastrointestinal stromal tumors after imatinib therapy.
Journal of Clinical Oncology · 2026-05-28
Overall survival analysis of a heavily pretreated population of patients with bone sarcomas treated with mecbotamab vedotin, a conditionally binding ADC targeting AXL.
Journal of Clinical Oncology · 2026-05-27
Efficacy of velzatinib (IDRX-42) in patients with advanced/metastatic GIST by line of therapy and circulating tumor DNA response in the phase 1/1b StrateGIST 1 trial.
Journal of Clinical Oncology · 2026-05-27
Velzatinib (IDRX-42) as 1L or 2L therapy for advanced gastrointestinal stromal tumors (GISTs) by <i>KIT</i> mutation status: A subset analysis of the phase 1/1b StrateGIST 1 study.
Journal of Clinical Oncology · 2026-05-27
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial
Nature Medicine · 2026-05-26
Multiomic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases
Clinical Cancer Research · 2026-04-30
Supplementary Figure S2 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
2025-12-17
Supplementary Figure S4 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
2025-12-17
Supplementary Figure S11 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
2025-12-17
supplementary table TS1 from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
2025-11-25
Supplementary Tables 1-4 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
2025-11-25
Supplementary Figure S1 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
2025-11-25
Supplementary Appendix 1 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
2025-11-25
Supplementary Figure S2 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
2025-11-25
Disrupted Independence—Supporting Adolescents and Young Adults with Sarcoma in Maintaining Autonomy: A Qualitative Study
Journal of Adolescent and Young Adult Oncology · 2025-11-18

Open author page on OpenAlex →